Cargando…

Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents

Anti-cancer agents exert therapeutic effects by damaging DNA. Unfortunately, DNA polymerases can effectively replicate the formed DNA lesions to cause drug resistance and create more aggressive cancers. To understand this process at the cellular level, we developed an artificial nucleoside that visu...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jung-Suk, Kim, Seol, Motea, Edward, Berdis, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522278/
https://www.ncbi.nlm.nih.gov/pubmed/28489578
http://dx.doi.org/10.18632/oncotarget.17254
_version_ 1783252139286462464
author Choi, Jung-Suk
Kim, Seol
Motea, Edward
Berdis, Anthony
author_facet Choi, Jung-Suk
Kim, Seol
Motea, Edward
Berdis, Anthony
author_sort Choi, Jung-Suk
collection PubMed
description Anti-cancer agents exert therapeutic effects by damaging DNA. Unfortunately, DNA polymerases can effectively replicate the formed DNA lesions to cause drug resistance and create more aggressive cancers. To understand this process at the cellular level, we developed an artificial nucleoside that visualizes the replication of damaged DNA to identify cells that acquire drug resistance through this mechanism. Visualization is achieved using "click" chemistry to covalently attach azide-containing fluorophores to the ethynyl group present on the nucleoside analog after its incorporation opposite damaged DNA. Flow cytometry and microscopy techniques demonstrate that the extent of nucleotide incorporation into genomic DNA is enhanced by treatment with DNA damaging agents. In addition, this nucleoside analog inhibits translesion DNA synthesis and synergizes the therapeutic activity of certain anti-cancer agents such as temozolomide. The combined diagnostic and therapeutic activities of this synthetic nucleoside analog represent a new paradigm in personalized medicine.
format Online
Article
Text
id pubmed-5522278
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55222782017-08-21 Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents Choi, Jung-Suk Kim, Seol Motea, Edward Berdis, Anthony Oncotarget Research Paper Anti-cancer agents exert therapeutic effects by damaging DNA. Unfortunately, DNA polymerases can effectively replicate the formed DNA lesions to cause drug resistance and create more aggressive cancers. To understand this process at the cellular level, we developed an artificial nucleoside that visualizes the replication of damaged DNA to identify cells that acquire drug resistance through this mechanism. Visualization is achieved using "click" chemistry to covalently attach azide-containing fluorophores to the ethynyl group present on the nucleoside analog after its incorporation opposite damaged DNA. Flow cytometry and microscopy techniques demonstrate that the extent of nucleotide incorporation into genomic DNA is enhanced by treatment with DNA damaging agents. In addition, this nucleoside analog inhibits translesion DNA synthesis and synergizes the therapeutic activity of certain anti-cancer agents such as temozolomide. The combined diagnostic and therapeutic activities of this synthetic nucleoside analog represent a new paradigm in personalized medicine. Impact Journals LLC 2017-04-19 /pmc/articles/PMC5522278/ /pubmed/28489578 http://dx.doi.org/10.18632/oncotarget.17254 Text en Copyright: © 2017 Choi et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Choi, Jung-Suk
Kim, Seol
Motea, Edward
Berdis, Anthony
Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents
title Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents
title_full Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents
title_fullStr Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents
title_full_unstemmed Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents
title_short Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents
title_sort inhibiting translesion dna synthesis as an approach to combat drug resistance to dna damaging agents
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522278/
https://www.ncbi.nlm.nih.gov/pubmed/28489578
http://dx.doi.org/10.18632/oncotarget.17254
work_keys_str_mv AT choijungsuk inhibitingtranslesiondnasynthesisasanapproachtocombatdrugresistancetodnadamagingagents
AT kimseol inhibitingtranslesiondnasynthesisasanapproachtocombatdrugresistancetodnadamagingagents
AT moteaedward inhibitingtranslesiondnasynthesisasanapproachtocombatdrugresistancetodnadamagingagents
AT berdisanthony inhibitingtranslesiondnasynthesisasanapproachtocombatdrugresistancetodnadamagingagents